



**amfAR**

The Foundation  
for AIDS Research

# DRIVING DISCOVERY THROUGH INNOVATION

ANNUAL REPORT | 2024

# OUR MISSION

amfAR, The Foundation for AIDS Research,  
is dedicated to ending the global AIDS  
epidemic through innovative research.

# CONTENTS

## **OUR IMPACT**

- 04 Research
- 10 Public Policy
- 16 TREAT Asia
- 20 Public Information

## **24 GRANTS, FELLOWSHIPS, AND AWARDS**

- 25 Research Grants and Fellowships
- 25 TREAT Asia Grants and Awards
- 28 Community Outreach Award

## **29 FINANCIAL SUMMARY**

## **32 LEADERSHIP AND ADVISORY COMMITTEES**

- 33 Board of Trustees
- 33 Scientific Advisory Committee
- 36 Program Advisory Council
- 36 Management Group



# From the Co-Chairs

Dear Friend of amfAR,

A year ago, we reported to you that seven people had been cured of HIV. That number has since risen to ten and will undoubtedly increase. This is a remarkable milestone and just one indication of continued momentum and progress in HIV research. To date, however, all of these cases have been achieved through stem cell transplants required to cure each patient's cancer, and we know that this high-risk procedure cannot be scaled up in any meaningful way.


With your support, amfAR researchers are striving to develop a safe and affordable cure that could be mass produced and administered worldwide, possibly in the form of a single shot. We will not end the HIV/AIDS pandemic without a cure that can be made available to all 40 million people living with HIV.

With the recent cuts in federal funding for HIV research—to the tune of almost \$1 billion—our work has taken on heightened importance. For scientists with promising, innovative ideas, amfAR's grant and fellowship support is indispensable. As always, every dollar you donate is invested only in studies of the highest caliber—studies that are bringing us closer to a cure.


As you will read in the following pages, our impact is felt far and wide. And, as a leader in biomedical research for 40 years, amfAR's work benefits the lives of people living with HIV and contributes to the prevention and treatment of other diseases and conditions, including tuberculosis, hepatitis, certain cancers, and mental health issues. In addition to our ironclad commitment to curing HIV and ending the HIV/AIDS pandemic, those overlapping efforts will continue as we leverage our knowledge and experience to address critical global health challenges.

We hope we can count on your continued support as we draw closer to a cure.

With gratitude,



**T. Ryan Greenawalt**  
Co-Chair of the Board of Trustees



**Kevin McClatchy**  
Co-Chair of the Board of Trustees



# Farewell and Thank You, Kevin


After more than three decades at amfAR and having served with distinction as Chief Executive Officer for the past 18 years, Kevin Robert Frost is retiring at the end of 2025.

Under Kevin's leadership, amfAR turned its research focus to curing HIV at a time when such a goal was widely derided in the scientific community as unrealistic. A five-year Countdown to a Cure for AIDS initiative, launched in 2014, raised more than \$50 million for new investments in cure research. Kevin oversaw the establishment of the amfAR Institute for HIV Cure Research with a \$20 million grant to UCSF, launched the amfAR Fund to Fight COVID-19, and successfully led the Foundation through the pandemic, among many accomplishments.

We are profoundly grateful to Kevin Frost for the passion, dedication, and inspiration he has brought to the role of CEO throughout his tenure and for the expert guidance he has provided to all of us on the Board of Trustees. His leadership has enabled amfAR to cement its reputation as a premier biomedical research institution and an authoritative voice on HIV/AIDS and global health, and to take giant steps towards a cure.

We extend our deepest appreciation and admiration to Kevin and we wish him well in his thoroughly deserved retirement.


**The Board of Trustees, amfAR**





# RESEARCH

While the development of powerful drugs that can keep HIV at bay is a remarkable success story in which amfAR played an important part, a cure continues to elude even the best scientific minds. With roughly 10 million people still lacking access to these lifesaving drugs, amfAR's unrelenting pursuit of a cure remains as urgent and as vitally important as ever.





# amfAR HAS BEEN AT THE FOREFRONT OF INNOVATIVE RESEARCH FOR **40** YEARS.

**Our dedication to discovery has led to breakthroughs in HIV treatment and prevention, cure research advances, cancer treatments, and vaccine development.**

**ANTIRETROVIRAL THERAPY:** Starting with protease inhibitors, which revolutionized the treatment of HIV and led to a drastic reduction in AIDS-related deaths, amfAR's research has contributed to the development of four of the six main classes of antiretroviral drugs in use today.

**HIV TRANSMISSION:** amfAR's first international research grant, awarded in 1987, supported a landmark study in Kenya that showed that HIV transmission can occur from females to males (in addition to vice versa).

**CCR5:** amfAR funded research showing that HIV almost always requires a protein called CCR5 to enter and infect cells. This breakthrough led to the development of the anti-HIV drug maraviroc, which blocks CCR5.

**CURING HIV:** The discovery of CCR5 paved the way to the first case of an HIV cure in 2008. This was made possible by a stem cell transplant using donor cells lacking the CCR5 gene. Several people have since been cured using the same method.

**MOTHER-TO-CHILD HIV TRANSMISSION:**

amfAR pioneered research that led to the use of antiretroviral drugs to block mother-to-child HIV transmission. As a result, this mode of transmission has been all but eliminated in many parts of the world.

**COVID-19:** amfAR grantee Dr. Drew Weissman and collaborator Dr. Katalin Karikó were awarded the 2023 Nobel Prize for their work on mRNA, which proved instrumental in the development of effective vaccines for Covid-19.

**mRNA:** amfAR funded groundbreaking research that in 2025 showed that dormant HIV could be reactivated using mRNA technology—making infected cells visible to the immune system and overcoming a major barrier to curing HIV.

**OTHER DISEASE BREAKTHROUGHS:** AIDS research is providing insights into a range of diseases, their causes, and their treatment. Better diagnostic methods, therapies to restore the immune system, newer preventive antibiotics and drugs, and new treatments for infectious diseases and cancer were all developed in the course of AIDS research.

# IN 2024, amfAR SUPPORTED 35 RESEARCH TEAMS INVOLVING 120 SCIENTISTS THROUGH GRANTS AND FELLOWSHIPS.

## Supporting Cutting-Edge Research

### What Is the HIV Reservoir and Why Is It the Main Barrier to a Cure?

While powerful drugs (antiretroviral therapy, or ART) prevent the spread of HIV or keep the virus in check in a person's body, a relatively small number of viruses remain hidden inside cells throughout the body. Secreted in this way, they can remain undetected and dormant for years. If therapy is stopped, these viruses reemerge and replicate, wreaking havoc on the immune system. The main challenge for researchers is that it is virtually impossible to distinguish between reservoir cells and uninfected cells.

A primary focus of amfAR's research, therefore, is identifying and eliminating these viral reservoirs.

### Harnessing the Power of Antibodies

A primary component of the immune system, antibodies are proteins that patrol the body to identify and neutralize invaders such as bacteria and viruses. They have enormous potential for fighting HIV, particularly an elite group of them known as broadly neutralizing antibodies.

Explains **Dr. Marina Caskey** of The Rockefeller University: "There's a subset of people with HIV whose immune systems, as they interact with the evolving virus, produce these antibodies that are very potent and active against a broad range of HIV strains. These are what we call bNAbs—broadly neutralizing antibodies."

**Dr. Rachel Rutishauser** and a team of co-investigators from the U.S. and Denmark, including **Drs. Steven Deeks** and **Michael Peluso** of

the **amfAR Institute for HIV Cure Research** at UCSF, are among several teams of amfAR-funded researchers exploring the potential of antibodies in curing HIV. They aim to determine why a cocktail of bNAbs administered at the time of temporarily stopping ART—as part of a clinical cure study—seems to improve control of HIV.

**Dr. James Termini**, of the University of Miami, is also studying anti-HIV bNAbs, which can control HIV replication in the absence of ART in animal models but have not been shown to eradicate HIV reservoirs. Dr. Termini aims to determine if using such antibodies with greatly enhanced ability to promote a form of anti-virus immunity known as ADCC, or antibody-dependent cellular cytotoxicity, might overcome this roadblock.

Meanwhile, **Dr. Mary Ann Checkley-Luttge**, of Case Western Reserve University, is testing two types of genetically engineered natural killer (NK) cells, to reduce the HIV reservoir. One of these cell types is genetically engineered to include CAR genes. CAR cells have been highly effective in the treatment of certain types of blood cancers. Combining the iNK cells with bNAbs, she and her team will assess their potency against HIV reservoirs in test-tube studies.

Finally, **Dr. Yiming Yin** of Boston Children's Hospital aims to genetically engineer B cells, imbuing them with the ability to target critical portions of the HIV envelope. Dr. Yin is testing a hypothesis that B cells expressing antibodies capable of neutralizing different HIV variants could reduce the size of the HIV reservoir and perhaps even replace antiretroviral therapy.





*"We are all pursuing this similar goal of treating our study participants better and providing a cure. And that's very exciting."*

– amfAR grantee Ya-Chi Ho, PhD, Yale University



## Can Anti-Cancer Agents Impact the HIV Reservoir?

Two amfAR-funded researchers are studying the ability of anti-cancer agents to take advantage of the HIV reservoir's vulnerabilities. **Dr. Michael Peluso** of UCSF is testing the immunity-stimulating ability of a drug used to treat bladder cancer to suppress HIV rebound in people after treatment interruption. And **Dr. Adam Spivak**, of the University of Utah, Salt Lake City, is investigating the potential of a leukemia drug for reducing the HIV reservoir by exploiting its ability to block T cell proliferation, a fundamental mechanism of HIV persistence.

## Understanding "Elite Controllers"


**Dr. Xu Yu** of Massachusetts General Hospital received additional amfAR funding to continue her study aimed at understanding why some people living with HIV are seemingly able to clear replication-competent HIV without the benefit of

ART or other medical interventions. "It's possible that such persons may have achieved a true cure of HIV infection, simply through the power of their immune system," says Dr. Yu. Understanding the mechanism that enables these "elite controllers" to naturally suppress HIV could help researchers devise ways to achieve the same effect among people living with HIV more broadly.

## Cultivating the Next Generation of HIV Researchers

For aspiring young HIV researchers, securing the funding necessary to become an independent HIV investigator is increasingly competitive. Through its Mathilde Krim Fellowships in Biomedical Research, amfAR is able to provide critical support to outstanding young scientists who represent the future of HIV research.

Senior Investigator Melanie Ott (right) and Postdoctoral Scholar Julia Prigann discuss data from a recent experiment at Gladstone Institutes. (Photo by Michael Short/Gladstone Institutes)



*"I've always admired amfAR for their focus on young people, on emerging talent, because this is absolutely critical for research on HIV and other diseases."*

**– Melanie Ott, PhD**  
Director, Gladstone Institute of Virology

In 2024, amfAR awarded two Mathilde Krim Fellowships in the amount of \$180,000 each to researchers attempting to close critical knowledge gaps in HIV cure research.

**Dr. Gabriel Duette** of Westmead Institute for Medical Research, Westmead, Australia, is studying how some people are able to control HIV after repeated strategic treatment interruptions. Dr. Duette is analyzing if these stop-and-start cycles lead to an increase of CD8+ killer T cells capable of clearing HIV-infected cells from the body and whether they can influence the genetic makeup of rebounding virus.

**Dr. Simone Richardson** of the National Institute for Communicable Diseases in Johannesburg, South Africa, is studying a segment of antibody molecules known as Fc, which regulate anti-HIV immune responses produced by potent antibodies. Dr. Richardson’s study could contribute to the development of both therapeutic and protective HIV vaccines.

## Sharing Knowledge

### What Can We Learn from the “Geneva Patient?”

Since the first person—the “Berlin patient”—was cured of HIV in 2008, nine others have been cured to date. In all cases, the individuals required a stem cell transplant to treat otherwise incurable cancers of the blood, and it was this stem cell transplant that eliminated both the cancer and the HIV.


In the first five cases, doctors used donor stem cells with a genetic mutation rendering cells nearly impervious to HIV infection. However, the “Geneva patient,” whose cure was confirmed in 2024, received “wild type” donor cells without the mutation.

Describing the case, researchers suggested it could open up a very different avenue of cure research. They believe that allogeneic immunity, or a graft-versus-host response—a key part of certain cancer cures following stem cell transplants with “normal” donors—may have been involved and might be replicated without requiring a transplant. The study authors include amfAR grantees **Drs. Asier Sáez-Cirión** (principal investigator), **Monique Nijhuis**, **Annemarie Wensing**, and **Javier Martínez Picado**.

### Scientific Publications and Presentations

amfAR grantees published their original research in a range of scientific journals in 2024. Publications and presentations include:

- *medRxiv*, **Dr. Steven Deeks**, timing of ART and reservoir development
- *AIDS*, **Dr. Jori Symons**, post-treatment control
- *Lancet HIV*, **IciStem researchers**, stem cell transplants and reservoir reduction
- *Emerging Microbes and Infections*, **Dr. Eric Arts**, latency reversing agent
- *HIV Research & Clinical Practice*, **Dr. Karine Dubé** personal experiences and cure trial
- Conference on Retroviruses and Opportunistic Infections: two studies on immune mechanisms of post-treatment control; **Dr. Toong Seng Tan** of the Ragon Institute of MGH, MIT and Harvard and Brigham and Women’s Hospital in Boston, characterizing sex-specific differences in the HIV reservoir



# IN 2024, 20 SCIENTIFIC PUBLICATIONS RESULTED FROM amfAR-FUNDED RESEARCH.





# PUBLIC POLICY

For 40 years, amfAR has been an authoritative, influential voice on HIV/AIDS and global health-related public policy. Its evidence-based, data-driven analyses of key issues are an invaluable and unbiased source of information for policymakers, advocates, researchers, journalists, and other key stakeholders. Through these and other advocacy strategies, amfAR is a forceful and effective champion on behalf of all people living with HIV.

## Bringing Expertise to Bear in the U.S. Response to HIV

amfAR's Washington, D.C.-based Andelson Office of Public Policy brings deep expertise in epidemiology, policy analysis, data monitoring, advocacy, and dissemination—highlighting both domestic and global developments that can either advance or hinder efforts to end the HIV epidemic.

Throughout the year, amfAR's Public Policy staff worked closely with decision-makers, scientists, media, advocates, and peer organizations to ensure that public policies are grounded in rigorous research and evidence. amfAR consulted regularly with members of the Biden administration, the Centers for Disease Control and Prevention, the National Institutes of Health, and the Department of Health and Human Services to discuss policy initiatives and promote an evidenced-based response to the U.S. HIV epidemic. Advocacy efforts focused on the limits of Southern states rejecting federal HIV funding and the impact of family planning services funding restrictions on the HIV response, among other concerns. In April 2024, amfAR staff were invited participants in the White House Minority Health Forum.

Through its advocacy, amfAR worked to strengthen the White House Office of National AIDS Policy amid restructuring efforts. Other meetings with White House officials included a presentation on the 2022 global mpox crisis and participation in a summit to accelerate the national HIV response in Hispanic/Latino communities. In July 2024, amfAR was invited to the first-ever White House Africa Care Forum, a Biden administration-led campaign aimed at building partnerships that would expand national cancer control plans in African countries.

amfAR staff members were invited by the CDC to participate in the search committee for directors to lead the institution's Division of HIV/AIDS Prevention and Division of STD Prevention.



*“As a person living with HIV, I have watched the urgency of the national and global HIV response recede over the past two decades. The challenge now is to engage a new generation of champions and to better understand how and where we can achieve epidemic control.”*

**– Greg Millett, MPH**  
amfAR Vice President  
and Director of Public Policy



## Increasing Effectiveness, Accountability of Global HIV Programs

The amfAR policy office maintains an active role in global advocacy and policy initiatives including attending PEPFAR Country Operational Planning meetings, the Global Fund Partnership Forum, the Global Fund board meeting, and the UN High-Level Meetings on HIV/AIDS. Policy staff engage in advocacy with House and Senate appropriations committees to secure strong global HIV budgets and closely track and respond to new global health policies.

In 2024, amfAR strengthened its already robust advocacy to protect PEPFAR, the highly successful U.S. President’s Emergency Plan for AIDS Relief, which has long enjoyed bipartisan support but is now under threat. amfAR participated in a PEPFAR five-year strategy meeting, providing input into the development and implementation of the PEPFAR Mid-Term Review process, and held several meetings with PEPFAR staff.

amfAR also met with the World Health Organization, the Global Fund, UNAIDS, and others to discuss the HIV implications of the Global Gag Rule, which prohibits foreign organizations that receive U.S. global health assistance from providing information, referrals or services for legal abortion, or advocating for access to abortion services—even with their own money.

Greg Millett, MPH, amfAR VP and Director of Public Policy, was appointed in 2024 to the Governing Council of the International AIDS Society (IAS) and to the IAS Executive Board, where he is helping unite the global HIV response across research, policy, and activism.

Additionally, the policy office plays a key role as a technical assistance provider for in-country community-led monitoring efforts in seven countries. In this role, amfAR engages with local activists and data collection teams to ensure high-quality data are produced for HIV service quality monitoring and advocacy with duty bearers.

Throughout 2024 amfAR staff published several studies in academic journals with far-reaching policy implications, including:

*There is no path to ending AIDS by 2030 without improving human rights in **Journal of the International AIDS Society***

“HIV and key populations”—a chapter for a report to the **World Bank** on financing the global HIV response

*Is HIV Epidemic Control by 2030 Realistic? in **The Lancet***


*Facilitators and barriers to community-led monitoring of health programs: Qualitative evidence from the global implementation landscape in **PLOS Global Public Health***

### The RISE Study

The Global Fund to Fight AIDS, Tuberculosis and Malaria invests more than \$5 billion a year to combat the three diseases. Since its founding in 2002, the Fund is estimated to have saved 65 million lives.

For many years amfAR has worked with partners on the ground in sub-Saharan Africa to improve the Global Fund’s effectiveness and accountability. amfAR was a cosponsor of a groundbreaking international study, launched in 2023, aimed at improving community engagement in the processes by which resources are allocated by the Global Fund.

The RISE (Representation, Inclusion, Sustainability, and Equity) study culminated in a report distilling the results of surveys and interviews with more than 650 participants from 83 countries. Offering







The RISE steering committee, which is made up of community CCM representatives, advocates, and global academic and research partners, including amfAR’s Dr. Jennifer Sherwood (back row, fourth from left) at first meeting in Casablanca, Morocco

*“Community involvement is key to fighting disease as vulnerable and minority populations are often overlooked or otherwise excluded from decision-making processes; we were determined to identify ways to bring more people to the table.”*

— Jennifer Sherwood, PhD, Director of Research, Public Policy, amfAR  
RISE report lead author





*“Throughout the course of the epidemic, success has been dictated by favorable public policies as much as by scientific breakthroughs. That’s why our advocacy program is every bit as impactful as our research initiatives.”*

—**Kevin Robert Frost**, Chief Executive Officer, amfAR

specific recommendations for improving community engagement in Global Fund grantmaking processes, the study was honored with the prestigious Robert Carr Research Award at the 2024 International AIDS Conference.

Supplementing its work on the RISE study, amfAR provided technical assistance for in-country community-led monitoring in 10 countries: South Africa, Lesotho, Malawi, Uganda, Kenya, Tanzania, Haiti, Zimbabwe, and (with amfAR’s TREAT Asia program) India and Indonesia. In this role, amfAR engages with local activists and data collection teams to ensure high-quality data are produced for HIV service quality monitoring and to inform advocacy initiatives.

## Empowering Advocacy Through Data and Expertise

Just as amfAR’s community-led monitoring efforts are driven by the painstaking collection and analysis of data, amfAR’s policy office maintains a suite of free databases that are invaluable resources for individuals and organizations working to secure and monitor funding for HIV-related programs in the U.S. and around the world. Users can assess overall trends and drill down to granular levels on the following topics:

- [Key Populations \(kpdata.amfar.org\)](https://kpdata.amfar.org)
- [Ending the HIV Epidemic in the U.S. \(ehe.amfar.org\)](https://ehe.amfar.org)
- [Opioid Epidemic & Health Indicators \(opioid.amfar.org\)](https://opioid.amfar.org)

- [PEPFAR Monitoring, Evaluation, and Reporting \(mer.amfar.org\)](https://mer.amfar.org)

- [PEPFAR Country/Regional Operational Plans \(copsdata.amfar.org\)](https://copsdata.amfar.org)

amfAR’s analyses have been replicated in articles and editorials across the political spectrum, published in various scientific journals, and have been used by federal agencies, Fortune 500 organizations, scientists, and the media. Data from PPO’s dashboards have been featured in *New York Times* editorials and National Academy of Sciences publications, and have won awards for emerging public health crises.

amfAR also worked with media to provide expert input on global health data gaps; the impact of HIV/AIDS on Black communities in the U.S.; how the American anti-abortion movement negatively impacts global health; the debate about the usefulness of the term “AIDS”; the HIV outbreak in Memphis, Tennessee; and the dearth of support for women and girls in the domestic HIV response; among others. Publication sites include European AIDS Treatment Group, *Ms. Magazine*, the *Memphis Commercial Appeal*, *The Hill*, *AidsSpan*, and *Global Health Now*.

amfAR staff was interviewed for a four-part documentary series on public health, *The Invisible Shield*, broadcast and streamed on PBS in March 2024. Staff also met with PBS officials to discuss global and national health issues.

Throughout the year, amfAR staff were invited to present at prestigious institutions such as the Penn Center for AIDS Research and the National Academy of Sciences, Engineering and Medicine’s Health and



amfAR's public policy office works closely with community-led monitoring initiatives in several countries, including South Africa's Ritshidze. Pictured here is a Ritshidze monitor interviewing public healthcare users about service delivery outside an Eastern Cape clinic. (Photo by Rian Horn/Courtesy Ritshidze)

Medicine Division on topics ranging from genomics and precision medicine to PEPFAR sustainability and using data to help drive public policy.

In 2024 amfAR published a policy brief—*Dual Epidemics: Leveraging HIV Infrastructure to Support HPV Prevention, Testing, and Cervical Cancer Elimination Goals*—examining the intersection of HIV and HPV and how service delivery for both could be integrated and tailored to the unique needs of women living with HIV.

## 25<sup>th</sup> International AIDS Conference

amfAR's policy office participated in several conferences throughout the year, presenting on topics ranging from improving community-led monitoring to helping strengthen the global health response for members of key populations.

At the 25th International AIDS Conference in Munich, Germany, amfAR staff presented seven abstracts on

topics including policies impacting transgender health, community-led monitoring in the age of PrEP, and leveraging implementation science to improve the HIV response. Highlights include:


- At a "Person-Centered Services" symposium, Greg Millett presented on the impact of structural racism on Black gay men in Europe and America accessing HIV prevention and treatment, specifically addressing challenges in accessing HIV status-neutral services.
- amfAR and Open Society Foundations co-organized a satellite session, "Undue influence: The outsized role of U.S. policy in global HIV and sexual and reproductive health and rights." Facilitated by Jennifer Sherwood, PhD, Director of Research, Public Policy, at amfAR, participants discussed how community advocates, researchers, and funders can develop strategies to counter U.S.-driven policies that restrict sexual and re-productive health and rights in order to improve health outcomes.





# TREAT ASIA

The Asia-Pacific region is home to nearly 7 million people living with HIV and accounts for 23% of all new infections globally. Treatment coverage varies across the region, where people living with and at risk for HIV are also challenged by co-infections such as hepatitis and tuberculosis, as well as mental health issues and drug use. With its network of 21 adult and 18 pediatric sites in 12 countries throughout the region, amfAR's TREAT Asia program brings researchers, health professionals, and advocates together to improve standards of care and expand access to treatment. Launched in 2001, TREAT Asia has become a model of regional collaboration on HIV/AIDS.



## Addressing the Needs of Women

According to **Dr. Jeremy Ross**, TREAT Asia's director of research, "Women living with and at risk of HIV face specific vulnerabilities, risks, and challenges. While a number of these get attention at a global level and in the context of better-resourced high-income country health systems, there are substantial gaps in associated clinical services in low- and middle-income countries and in the Asia-Pacific region."

Drawing on the expertise of Dr. Ross and network partners, TREAT Asia convened its first think tank addressing clinical, research, and policy needs related to women and HIV in the Asia-Pacific region with the goal of informing TREAT Asia's research plans for this vulnerable and often neglected population.

Ongoing TREAT Asia studies are analyzing pregnancy outcomes among women living with HIV. Researchers are also studying human papillomavirus (HPV)—the primary cause of cervical cancer—among adolescents, as well as cervical dysplasia and HPV infection in women living with HIV.

## Taking the Lead on Hepatitis

The Asia-Pacific region is especially hard hit by chronic viral hepatitis, bearing 62% of the global burden of hepatitis B and 32% of hepatitis C. In Indonesia alone, 18.9 million people are living with chronic hepatitis B or C.

In a major advance, the Indonesian Ministry of Health in 2024 adopted program indicators measuring hepatitis care delivery that were developed through TREAT Asia's Community-led Monitoring in Asia project. Yayasan Peduli Hati Bangsa, a Jakarta-based nonprofit organization addressing the needs of people living with HIV and hepatitis, helped develop the indicators and has been advocating for their broader uptake.

The hepatitis indicators include assessments of services such as access to screening and diagnosis,

treatment, and treatment monitoring, as well as access to vaccination against hepatitis B. The guidelines are being implemented as part of Indonesia's 2025–2029 National Viral Hepatitis Action Plan.

In 2024, TREAT Asia published and disseminated a fact sheet on *Understanding WHO Guidelines for the Prevention, Care, Diagnosis, and Treatment of People with Chronic Hepatitis B Infection*.

## Improving Health for Children and Youth

In 2023, 12% of all AIDS-related deaths occurred in children, who make up only 3% of all people living with HIV. The study of pediatric and adolescent HIV has long been a focus of TREAT Asia, whose pediatric HIV database includes clinical data on more than 6,400 children and adolescents across the region.

In 2024, researchers reported the results of a multi-year study of the long-term treatment outcomes of adolescents and young adults living with HIV. Led by **Linda Aupibul, MD, MPH**, of Chiang Mai University, with support from ViiV Healthcare, the study assessed issues such as retention in care, mortality, quality of life, mental health, behavioral outcomes, alcohol and substance use, and sexual and reproductive health. A special focus included helping adolescents and young adults transition from pediatric to adult care.

Most who transitioned into adult care did so successfully, with 78% achieving suppression of their HIV virus, the study found. However, 7% died, many of them only a few years after the transition, and 88% of these deaths were AIDS-related. Dr. Aupibul noted that those who died often shared similar stories: "being severely immunosuppressed at their last clinic follow-up, then lost to follow-up, then hospitalized due to opportunistic infection or passing away at home."

To counter the high mortality rate, one thing became clear—the need for better support systems for the transition to adult care.





*“The cervical health needs of women in the Asia-Pacific region are underserved and under-researched. Network sites like Prof. Dr. Ngoerah Hospital in Indonesia play a vital role in addressing the bi-directional and mutually reinforcing risks of HIV and cervical cancer.”*

— Annette Sohn, MD, PhD  
amfAR Vice President and Director, TREAT Asia



## Addressing Mental Health

The objective of TREAT Asia’s CHIMERA program (Capacity development for **HIV** and **mental** health **research** in **Asia**) is to address the dual and interlinked burdens of HIV and mental health. Co-led by Principal Investigators **Dr. Annette Sohn**, amfAR vice president and director of TREAT Asia, and **Dr. Milton Wainberg** of Columbia University, the program aims to build teams within the Asia-Pacific with the capacity to lead regional HIV-mental health-implementation science research that informs public health policy and improves clinical care.

CHIMERA brings together stellar training faculty from academic centers and public health and development agencies within the region and across the world, and builds on existing NIH-funded mental health research being conducted through leDEA Asia-Pacific. Fellows presented poster abstracts at the HIV and Aging Conference in Washington, D.C., in October 2023, gave oral presentations at the Global leDEA Meeting in Côte d’Ivoire in April, and participated in the Asia-Pacific AIDS & Co-infections Conference in Singapore in June.

## Championing Data-Driven Research

TREAT Asia manages the Asia-Pacific section of the International epidemiology Databases to Evaluate AIDS (leDEA), a global collaboration established by

the U.S. National Institute of Allergy and Infectious Diseases. leDEA is central to international research in which TREAT Asia participates, ranging from studies on treatment outcomes of HIV and pulmonary TB to medical and mental health challenges faced by adolescents living with HIV.


The information gathered from clinical sites in three TREAT Asia databases—TAHOD, TAHOD Low-Intensity Transfer, and the TREAT Asia Pediatric HIV Observational Database—continues to inform the development of more effective research and treatment programs and help define treatment standards specific to HIV/AIDS in Asia.

## Sharing Research Findings

TREAT Asia investigators published 22 scientific papers in peer-reviewed medical journals in 2024.

These findings are shared in part through the participation of TREAT Asia investigators in regional and international conferences. TREAT Asia had a strong presence at the 2024 International AIDS Conference, for example. **Giten Khwairakpam**, TREAT Asia’s program manager, community and policy, and numerous TREAT Asia partner investigators and affiliates also presented at the conference.






*TREAT Asia's community-led monitoring project in Indonesia led to that country's Ministry of Health adopting program indicators measuring hepatitis B and hepatitis C care delivery that were developed by clients, with the help of data enumerators (pictured here). (Photo courtesy Yayasan Peduli Hati Bangsa)*

# PUBLIC INFORMATION

Keeping HIV/AIDS in the public consciousness as an issue that continues to warrant attention, action, and financial support in the face of countless competing causes and crises is a constant challenge. Misconceptions and misinformation about HIV abound to this day and must be confronted and corrected. Stigma and discrimination against people living with the virus persist in the U.S. and around the world. So the task of getting the facts out about HIV and conveying the urgency of amfAR's mission requires creativity and persistence across a range of strategies and platforms.





*"Deeply grateful to be empowered in raising my voice against HIV stigma.... Thank you amfAR for doing the necessary research to end HIV and for the opportunity to speak on an issue that's so important to me."*

— Ian Bicko, Executive Director, Project Lazarus, and pro beach volleyball athlete



## Why Do We Need a Cure?

The answer to this question may seem self-evident. But with the widespread availability (in much of the world) of powerful antiretroviral drugs that enable people to stay healthy and live a normal lifespan, the question is worth addressing. To that end, and as a means of educating the public, in December 2023 amfAR commissioned a Harris Poll that asked a sample of approximately 2,000 adults in the U.S. about their knowledge of and attitudes toward HIV as a public health threat, HIV treatment and prevention, and HIV cure research. The results served to explain exactly why we urgently need a cure for HIV and were shared widely in print and online.

---

# 72%

**of American adults believe that researchers should focus on curing HIV as much as they focus on curing other diseases such as cancer**

---

## Boosting HIV Awareness Across Platforms

**Social Media:** amfAR has vigorously expanded its presence in the social media arena, reaching large numbers of people, including a younger demographic that is often less educated about HIV and the AIDS epidemic. Posts in FY2024 covered topics such as HIV funding priorities in the American South, HIV criminalization, cuts in HIV funding, PrEP access, the importance of reauthorizing PEPFAR, and amfAR research and policy news.

As it typically does, amfAR's flagship annual benefit event, amfAR Gala Cannes during the Cannes International Film Festival, gained global media attention and raised millions of dollars for amfAR's lifesaving research programs. The event garnered over 3.3 million video views with 6.5 million impressions on owned social channels and 46,000 total mentions of amfAR online, and gained 10,350 followers across channels.

**On the Web:** The Foundation's website—[www.amfar.org](http://www.amfar.org)—features news, interviews, and original articles covering HIV research, policy, the global epidemic, and amfAR programs and activities. The website attracts an average 36,500 monthly visits.

For the 2024 International AIDS Conference in Munich, Germany, amfAR created a web platform showcasing presentations and workshops led by amfAR staff and providing daily in-person reporting.



**<< Survey Method:** This statistic is from a survey conducted online within the United States by the Harris Poll on behalf of amfAR in 2023 among 2,053 U.S. adults ages 18 and older.



*“Few in the entertainment community have done as much to support the fight against AIDS as **Dionne Warwick**. We are so grateful to her for her unwavering commitment to the health and wellbeing of all people living with HIV and we are thrilled to be able to recognize Dionne’s decades of generosity and activism by presenting her with amfAR’s Award of Courage.”*

— **Kevin Robert Frost**, Chief Executive Officer, amfAR

**Digital, Print, and Video:** amfAR produces periodicals in both print and digital formats, including its newsletter, *Innovations*, published twice a year and distributed to about 16,000 readers, and a monthly e-mail newsletter, *Insights*, distributed to approximately 20,000 recipients.

amfAR creates and distributes reports, press releases, and updates on major HIV/AIDS issues and conducts public service advertising campaigns that have been instrumental in educating policymakers, healthcare professionals, people living with HIV/AIDS, and the public. amfAR’s Public Information team also works closely with the Public Policy Office and TREAT Asia staff (see above) to produce a wide range of issue briefs, facts sheets, infographics, and reports.

For World AIDS Day on December 1, 2023, amfAR’s public information team produced a video featuring the organization’s CEO, program heads, board co-chairs, and celebrity supporters, offering insights into progress on HIV/AIDS, domestic and foreign HIV policy, and current HIV research.

## In the Press

amfAR continued to work closely with the media to raise the profile of HIV/AIDS, both domestically and internationally, and to help ensure the accuracy of HIV-related press coverage. amfAR garnered approximately 5,430 mentions across media in FY2024. Articles and reports involving amfAR—many of which included interviews with staff—were carried in numerous media outlets, including *The New York Times*, *The Washington Post*, *Journal of the International AIDS Society*, *The Lancet*, *The*

*Guardian*, *Billboard*, *The Hill*, *Medscape*, *POZ*, *Positively Aware*, *Paris Match*, *People*, *Politico*, *Vanity Fair*, *Variety*, *Vogue*, *Women’s Wear Daily*, *Elle*, *Esquire*, *The Hollywood Reporter*, *Town & Country*, *Reuters*, *AP News*, *Yahoo*, *CBS News*, and *ABC News*.

## Support from Public Figures

amfAR’s public awareness efforts are greatly enhanced by the committed support of public figures who lend their voices and donate their time, talents, and resources—most often through benefit events—to help sustain the Foundation’s mission. Support of amfAR from prominent public figures began with the late Dame Elizabeth Taylor, amfAR’s Founding International Chairman, and many others have followed in her footsteps. amfAR is profoundly grateful for the continuing support of celebrities from all over the world.

Celebrity supporters throughout the year included Pedro Almodóvar, Jonathan Bailey, Antonio Banderas, Angela Bassett, Kate Beckinsale, Cher, Alan Cumming, Willem Dafoe, Jason Derulo, Colman Domingo, Cynthia Erivo, Richard Gere, Goldie Hawn, Tommy Hilfiger, Kris Jenner, Nick Jonas, Milla Jovovich, Heidi Klum, Diane Kruger, Julian Lennon, Eva Longoria, Andie MacDowell, Julianna Margulies, Demi Moore, Catherine O’Hara, Vanessa Redgrave, Joely Richardson, Amber Riley, Coco Rocha, Michelle Rodriguez, Carine Roitfeld, Kelly Rowland, Alexander Skarsgård, Sylvester Stallone, Sting, Ellen von Unwerth, Dionne Warwick, Rumer Willis, Jeffrey Wright, Michelle Yeoh, and Zhang Ziyi.






*"Let's step up together so we can look our kids in the eye and tell them we did everything we possibly could to rid the world of AIDS, and that ultimately we succeeded."*

— **Michelle Yeoh**, Actor and amfAR Supporter



**GRANTS,  
FELLOWSHIPS,  
AWARDS**





## 2024 RESEARCH GRANTS AND FELLOWSHIPS

All projects below were awarded funding during the period October 1, 2023, through September 30, 2024.

### amfAR RESEARCH CONSORTIUM ON HIV ERADICATION (ARCHE)

Characterizing non-direct antiviral functions of bNAbs

Rachel Rutishauser, MD, PhD  
University of California, San Francisco  
San Francisco, CA  
\$622,272

Characterizing loss or eradication of activatable reservoir (CLEAR) in PLHIV (extension)

Xu Yu, PhD  
Massachusetts General Hospital  
Boston, MA  
\$1,370,683

### TARGET GRANTS

Targeting the HIV viral reservoir with long-term delivery of broadly neutralizing antibodies with markedly enhanced ADCC

James Termini, PhD  
University of Miami  
Coral Gables, FL  
\$480,000

Reducing HIV reservoirs with genetically engineered iPSC-derived NK cells

Mary Ann Checkley-Luttge, PhD  
Case Western Reserve University  
Cleveland, OH  
\$497,977

An adaptive engineered B cell-based cure of HIV-1

Yiming Yin, PhD  
Boston Children's Hospital  
Boston, MA  
\$240,000

Dasatinib for HIV reservoir reduction

Adam Spivak, MD  
University of Utah, Salt Lake City  
Salt Lake City, UT  
\$480,000

Interleukin-15 to promote post-ART control of HIV (INTERRUPT-HIV)

Michael Peluso, MD  
University of California, San Francisco  
San Francisco, CA  
\$480,000



*"Since childhood, I dreamed of achieving scientific breakthroughs to benefit society. By furthering my research into the elimination of HIV infection, the Mathilde Krim Fellowship brings me another step closer to this dream."*

– **Gabriel Duette, PhD**

Westmead Institute for Medical Research  
amfAR Mathilde Krim Fellow

### MATHILDE KRIM FELLOWSHIPS IN BIOMEDICAL RESEARCH

Delineating immuno-virological factors contributing to HIV control during consecutive analytical treatment interruptions

Gabriel Duette, PhD  
Westmead Institute for Medical Research  
Westmead, Australia  
\$179,995

Evolution of Fc effector function in HIV neutralizing lineages

Simone Richardson, PhD  
National Institute for Communicable Diseases  
Johannesburg, South Africa  
\$179,164

Role of glutaminolysis in HIV persistence and associated inflammation (phase 2)

Leila Giron, MSc, PhD  
The Wistar Institute  
Philadelphia, PA  
\$50,000

## 2024 TREAT ASIA GRANTS AND AWARDS

All projects below were awarded funding during the period October 1, 2023, through September 30, 2024.

<sup>1</sup>Supported by U.S. National Institutes of Health Federal award number U01AI069907, with funds from the National Institute of Allergy and Infectious Diseases, the *Eunice Kennedy Shriver* National Institute of Child Health and Human Development, the National Institute of Diabetes and Digestive and Kidney Diseases, the National Institute on Drug Abuse, the National Heart, Lung, and Blood Institute, the National Institute on Alcohol Abuse and Alcoholism, the National Cancer Institute, the National Institute of Mental Health, and the Fogarty International Center.



<sup>2</sup>Supported by U.S. National Institutes of Health Federal award number D43TW011302, funded by the Fogarty International Center and the National Institute of Mental Health.

<sup>3</sup>Supported with funds provided by ViiV Healthcare.

<sup>4</sup>Supported with funds provided by amfAR's broad base of donor support.

## AUSTRALIA

### University of New South Wales

Sydney  
Kathy Petoumenos, PhD  
IeDEA Asia-Pacific Research Collaboration:  
Data Management and Analysis Center  
\$680,083<sup>1</sup>

### AUSTRALIAN HIV OBSERVATIONAL DATABASE (AHOD) SITES

#### Sexual Health and HIV Service In Metro North

Brisbane  
Angela Smith, MBBS  
\$5,925<sup>1</sup>

#### Cairns and Hinterland Hospital and Health Service (CHHHS)

Cairns  
Hardeep Kaur Kang, MBChB (UK), FACHSHM, FRCP (UK), MRCP (UK)  
\$6,150<sup>1</sup>

#### Sunshine Coast Hospital and Health Service,

##### Nambour Hospital

Caloundra  
David Sowden, MBBS  
\$7,530<sup>1</sup>

#### RPA Sexual Health, Sydney Local Health District

Camperdown  
David Templeton, PhD  
\$8,975<sup>1</sup>

#### Melbourne Sexual Health Centre

Carlton  
Richard Teague, MBBS (Monash Uni), FRACGP, FRACHSHM  
\$6,075<sup>1</sup>

#### Monash Medical Centre

Clayton  
Ian Woolley, MBBS, FRACP  
\$11,380<sup>1</sup>

#### Victorian HIV Service, Department of Infectious Diseases, The Alfred Hospital

Melbourne  
Jennifer Hoy, AM, MBBS, FRACP, FAHMS  
\$9,340<sup>1</sup>

#### Mid North Coast Local Health District

Port Macquarie  
Vincent Cornelisse, BSc, MBBS, PhD, FRACGP, FACHSHM, FACHAM, FRCP  
\$6,300<sup>1</sup>

#### Gold Coast Hospital and Health Service

Southport  
Caroline Lade, MBBS, FRACGP, FACHSHM  
\$7,500<sup>1</sup>

#### East Sydney Doctors

Sydney  
Heather Farlow  
\$7,850<sup>1</sup>

#### Holdsworth House Medical Practice

Sydney  
Mark Bloch, MD  
\$8,425<sup>1</sup>

#### St. Vincent's Hospital Sydney Limited

Sydney  
Andrew Carr, MD  
\$9,860<sup>1</sup>

#### Taylor Square Private Clinic

Sydney  
Mark John O'Reilly, FACHSHM, FRACGP, MPH, BMED, BAPSc (MRT)  
\$4,300<sup>1</sup>

#### Centre for Disease Control, Northern Territory Department of Health

Tiwi  
Manoji Gunathilake, MBBS, MD, FACHSHM, AFRACMA  
\$1,665<sup>4</sup>

#### Western Sydney Local Health District

Westmead  
Rohan Bopage, MBBS, FRACP, MMed STD/HIV, FACHSHM  
\$3,930<sup>1</sup>

## CAMBODIA

#### National Center for HIV/AIDS, Dermatology and STD

Phnom Penh  
Vohith Khol, MD, MSc  
The TAHOD Continuum of Care (TAHOD-CC) Study  
\$20,000<sup>1</sup>

#### The IeDEA Tuberculosis Sentinel Research Network (TB-SRN) Study

\$78,076<sup>1</sup>

#### TREAT Asia Pediatric HIV Observational Database (TApHOD) Study

\$31,910<sup>1</sup>

## CHINA

#### Queen Elizabeth Hospital

Hong Kong SAR  
Man Po Lee, MBBS  
The TAHOD Continuum of Care (TAHOD-CC) Study  
\$28,600<sup>4</sup>

## INDIA

#### The Voluntary Health Services, VHS Infectious Diseases Medical Centre

Chennai  
Nagalingeswaran Kumarasamy, MD, MBBS, PhD  
The TREAT Asia HIV Observational Database (TAHOD) Study  
\$35,000<sup>1</sup>



**TREAT Asia Pediatric HIV Observational Database (TAPHOD) Study**  
\$4,740<sup>1</sup>

**Community Network for Empowerment (CoNE)**  
Imphal West  
Rajkumar Nalinikanta  
Community-led monitoring to improve quality HIV, HBV and HCV services in Manipur  
\$12,600<sup>3</sup>

**BJ Medical College & Sassoon General Hospitals**  
Pune  
Rohidas T Borse, MD, MBBS  
The TREAT Asia HIV Observational Database (TAHOD) Study  
\$17,500<sup>1</sup>

**leDEA Sentinel Research Network (SRN)—Asia-Pacific Study**  
\$103,384<sup>1</sup>; \$1,149<sup>1</sup> (Supplement)

**Lung Morbidity Cohort Study**  
\$85,118<sup>1</sup>

**Aarti Kinikar, MD DCH, DNB, MRCP-Pediatrics UK**  
TREAT Asia Pediatric HIV Observational Database (TAPHOD) Study  
\$18,060<sup>1</sup>

**Institute of Infectious Diseases**  
Pune  
Sanjay Pujari, MD, AAHIVS, MBBS  
The TREAT Asia HIV Observational Database (TAHOD) Study  
\$29,400<sup>1</sup>

## INDONESIA

**Hasan Sadikin Hospital**  
Bandung  
Anggraini Alam, dr., Sp.A(K)  
TREAT Asia Pediatric HIV Observational Database (TAPHOD) Study  
\$11,160<sup>1</sup>

**Faculty of Medicine, Udayana University - Prof. Dr. I.G.N.G. Ngoerah General Hospital**  
Denpasar  
I Ketut Agus Somia, SpPD, KPTI, MD, PhD  
The TAHOD Continuum of Care (TAHOD-CC) Study  
\$17,500<sup>1</sup>

**Ketut Dewi Kumara Wati, MD, PhD**  
TREAT Asia Pediatric HIV Observational Database (TAPHOD) Study  
\$12,600<sup>1</sup>

**Cipto Mangunkusumo General Hospital**  
Jakarta  
Dina Muktiarti, SpA(K)  
TREAT Asia Pediatric HIV Observational Database (TAPHOD) Study  
\$14,836<sup>1</sup>

**Evy Yuniastuti, Sp.PD-KAI**  
The TAHOD Continuum of Care (TAHOD-CC) Study  
\$19,040<sup>1</sup>

**Behavioral Economic Approaches for Tuberculosis Preventive Therapy in Asia Pacific leDEA (BEAT TB ASIA)**  
\$19,872<sup>1</sup>

**Yayasan Peduli Hati Bangsa**  
Pagedangan  
Claudius Novchovick Mone Iye  
Improving HIV and Viral Hepatitis Services in Indonesia through community-led monitoring and participation  
\$12,000<sup>3</sup>

## JAPAN

**National Center for Global Health and Medicine**  
Tokyo  
Haruka Uemura, MD, PhD  
The TAHOD Continuum of Care (TAHOD-CC) Study  
\$21,700<sup>1</sup>; \$2,500<sup>1</sup> (Supplement)

## SOUTH KOREA

**University-Industry Foundation, Yonsei University Health System**  
Seoul  
Jun Yong Choi, MD, PhD  
The TAHOD Continuum of Care (TAHOD-CC) Study  
\$18,800<sup>1</sup>

## MALAYSIA

**Universiti Malaya**  
Kuala Lumpur  
Reena Rajasuriar, PhD  
The Mental Health Service Integration Study  
\$36,625<sup>1</sup>

**Universiti Malaya Medical Centre**  
Kuala Lumpur  
Raja Iskandar Shah Raja Azwa, MBChB, MRCP, DipGUM, DSRH, DIP HIV, CCT  
The TAHOD Continuum of Care (TAHOD-CC) Study  
\$21,700<sup>1</sup>

**Sungai Buloh Hospital**  
Sungai Buloh  
Yasmin Mohamed Gani, MD  
The TAHOD Continuum of Care (TAHOD-CC) Study  
\$15,000<sup>1</sup>

## PHILIPPINES

**LoveYourself, Inc.**  
Bagubayan Taguig  
Ronivin Garcia Pagtakhan, MD, PhD  
Southeast Asia Cohort Study  
\$35,241<sup>1</sup>

**Research Institute for Tropical Medicine**  
Muntinlupa City  
Rossana A. Ditangco, MD  
The TAHOD Continuum of Care (TAHOD-CC) Study  
\$15,000<sup>1</sup>

**The Mental Health Service Integration Study**  
\$33,964<sup>1</sup>

**Adolescent and Young Adult network of leDEA (AYANI) Study**  
\$18,593<sup>1</sup>



Aileen Gianan Gascon, MD, FPCP, FPSMID  
Behavioral Economic Approaches for  
Tuberculosis Preventive Therapy in Asia  
Pacific leDEA  
(BEAT TB ASIA)  
\$14,230<sup>1</sup>

## SINGAPORE

**Tan Tock Seng Hospital**  
Singapore  
Choy Chiaw Yee, MBBS  
The TAHOD Continuum of Care (TAHOD-CC)  
Study  
\$12,000<sup>1</sup>

## TAIWAN

**Taipei Veterans General Hospital**  
Taipei City  
Hsin-Pai Chen, MD, PhD  
The TAHOD Continuum of Care (TAHOD-CC)  
Study  
\$18,880<sup>1</sup>

## THAILAND

**Chulalongkorn University**  
Bangkok  
Thanyawee Puthanakit, MD  
Adolescent and Young Adult network of leDEA  
(AYANI) Study  
\$25,329<sup>1</sup>

A cost-utility analysis of an integrated mental  
health collaborative care service for adolescents  
& young adults  
\$23,704<sup>1</sup>

The association between changes in risk-taking  
behavior and neuropsychological outcomes and  
brain connectivity  
\$39,960<sup>1</sup>

**HIV-NAT / Thai Red Cross AIDS Research Centre**  
Bangkok  
Anchalee Avihingsanon, MD, PhD  
The TAHOD Continuum of Care (TAHOD-CC)  
Study  
\$17,500<sup>1</sup>

The Mental Health Service Integration Study  
\$30,819<sup>1</sup>

The leDEA Tuberculosis Sentinel Research  
Network (TB-SRN) Study  
\$52,111<sup>1</sup>

Plasma-Based Biomarkers for Detecting  
Alzheimer's Disease in Virologically Suppressed  
Older People with HIV  
\$70,000<sup>1</sup>

Kiat Ruxrungham, MD, MSc  
Thailand National Health Registries Study  
\$19,000<sup>1</sup>

**Institute of HIV Research and Innovation  
Foundation (IHRI)**  
Bangkok  
Nittaya Phanuphak, MD, PhD  
The Mental Health Service Integration Study  
\$33,247<sup>1</sup>

Anal HSIL screening algorithm  
optimization Study  
\$26,088<sup>1</sup>; \$17,760<sup>1</sup> (Supplement)

Southeast Asia Cohort Study  
\$65,593<sup>1</sup>

Substance use in YMSM  
\$64,442<sup>1</sup>

**Rainbow Sky Association of Thailand**  
Bangkok  
Somporn Saiwaew, PhD  
Southeast Asia Cohort Study  
\$47,268<sup>1</sup>

**Ramathibodi Hospital, Mahidol University**  
Bangkok  
Sasisopin Kiertiburanakul, MD, MHS  
The TAHOD Continuum of Care (TAHOD-CC)  
Study  
\$20,240<sup>1</sup>

**Chiang Mai University Research Institute for  
Health Sciences**  
Chiang Mai  
Romanee Chaiwarith, MD, MHS  
The TAHOD Continuum of Care (TAHOD-CC)  
Study  
\$15,000<sup>1</sup>

Tavitiya Sudjaritruk, MD, ScM, PhD  
S-BETAH-Adolescent suicidal behavior among  
Thai adolescents living with HIV Study  
\$70,151<sup>1</sup>

Adolescent and Young Adult network of leDEA  
(AYANI) Study  
\$23,270<sup>1</sup>

**Chiangrai Prachanukroh Hospital**  
Chiang Rai  
Suwimon Khusuwan, MD  
The TAHOD Continuum of Care (TAHOD-CC)  
Study  
\$24,760<sup>1</sup>

The leDEA Tuberculosis Sentinel Research  
Network (TB-SRN) Study  
\$98,753<sup>1</sup>

Pradthana Ounchanum, MD  
S-BETAH-Adolescent suicidal behavior among  
Thai adolescents living with HIV study  
\$14,477<sup>1</sup>

**Srinagarind Hospital, Khon Kaen University**  
Khon Kaen  
Pope Kosalaraksa, MD  
S-BETAH-Adolescent suicidal behavior among  
Thai adolescents living with HIV study  
\$17,615<sup>1</sup>

## USA

**Johns Hopkins University**  
Baltimore  
Amita Gupta, MD, MHA  
leDEA Asia-Pacific: JHU/BJGMC cohort and  
substudies  
\$221,622<sup>1</sup>

**Columbia University**  
New York  
Claude Ann Mellins, PhD  
Suicidal Behavior Among Thai Adolescents  
Living with HIV (S-BETAH) Study: Technical  
Support  
\$19,968<sup>1</sup>

Milton Wainberg, MD  
Mental Health Service Integration Study: Study  
Oversight and Technical Support  
\$19,000<sup>1</sup>

Capacity development for HIV and mental health  
research in Asia (CHIMERA)  
\$27,000<sup>2</sup>

## VIETNAM

**Bach Mai Hospital**  
Hanoi  
Do Duy Cuong, MD, PhD  
The TAHOD Continuum of Care (TAHOD-CC)  
Study  
\$17,500<sup>1</sup>

**National Hospital for Tropical Diseases**  
Hanoi  
Thach Ngoc Pham, MD, PhD  
leDEA Sentinel Research Network (SRN)—Asia-  
Pacific Study  
\$67,878<sup>1</sup>

**Vietnam National Children's Hospital**  
Hanoi  
Nguyen Van Lam, MD, MSc, PhD  
TREAT Asia Pediatric HIV Observational  
Database (TApHOD) Study  
\$15,000<sup>1</sup>

**Children's Hospital 1**  
Ho Chi Minh City  
Du Tuan Quy, MD  
TREAT Asia Pediatric HIV Observational  
Database (TApHOD) Study  
\$28,020<sup>1</sup>

**Children's Hospital 2**  
Ho Chi Minh City  
Qui Dinh Nguyen, MD  
TREAT Asia Pediatric HIV Observational  
Database (TApHOD) Study  
\$21,660<sup>1</sup>

**Glink Vietnam Social Enterprise Company  
Limited**  
Ho Chi Minh City  
Thanh Le Minh  
Southeast Asia Cohort Study  
\$23,465<sup>1</sup>

## 2024 COMMUNITY OUTREACH AWARD

The funding listed below was awarded  
during the period October 1, 2023,  
through September 30, 2024.

**Community Outreach Award: Operating  
Support for HIV Programs**  
Compass, Inc.  
Lake Worth, FL  
\$25,000





# FINANCIAL SUMMARY



# STATEMENT OF ACTIVITIES

For the year ended  
**September 30, 2024**

## Public Support and Revenue

Public support	\$ 3,732,421
Special events	8,242,321
Planned giving	3,889,731
Government funding	8,282,568
Investment income and other revenue	6,902,478
<b>Total public support and revenue</b>	<b>\$ 31,049,519</b>


## Operating Expenses

Research	\$ 9,580,936
TREAT Asia	5,422,788
Public Policy	2,123,875
Public Information	3,747,325
<b>Total program services</b>	<b>\$ 20,874,924</b>

Fundraising	6,140,650
Management and general	2,589,964
<b>Total supporting services</b>	<b>\$ 8,730,614</b>

**Total expenses \$ 29,605,538**

Change in net assets	\$ 1,443,981
Net assets, beginning of year	32,369,625
<b>Net assets, end of year</b>	<b>\$ 33,813,606</b>



## EXPENSES



PROGRAM  
**\$20,874,924**




FUNDRAISING  
**\$6,140,650**



MANAGEMENT AND GENERAL  
**\$2,589,964**

**\$29,605,538**  
TOTAL EXPENSES





## PROGRAM EXPENSES



**\$9,580,936**

RESEARCH



**\$5,422,788**

TREAT ASIA



**\$2,123,875**

PUBLIC POLICY



**\$3,747,325**

PUBLIC  
INFORMATION

**\$20,874,924**

TOTAL PROGRAM EXPENSES

## STATEMENT OF FINANCIAL POSITION

### Assets

Cash and investments	\$ 39,519,850
Pledges and receivables, net	5,159,860
Prepaid expenses and other assets	2,514,908
Furniture, equipment, and leasehold improvements, net	2,062,644
Right of use asset, net—operating leases	4,096,770
<b>Total Assets</b>	<b>\$ 53,354,032</b>

### Liabilities

Accounts payable and accrued expenses	\$ 6,125,286
Line of credit	1,398,459
Grants and fellowships payable, net	32,446
Deferred support and refundable advances	6,610,061
Other long-term liabilities	525,215
Lease liabilities—operating leases	4,848,959
<b>Total liabilities</b>	<b>\$ 19,540,426</b>

### Net assets

Net assets beginning of year	\$ 32,369,625
Change in net assets	1,443,981
<b>Net assets end of year</b>	<b>\$ 33,813,606</b>

**Total liabilities and net assets** **\$ 53,354,032**



# LEADERSHIP AND ADVISORY COMMITTEES





## BOARD OF TRUSTEES

Fiscal Year 2024

### Co-Chair

**T. Ryan Greenawalt**  
Managing Director  
Ramirez & Co  
New York, NY

### Co-Chair

**Kevin McClatchy**  
Chairman of the Board  
The McClatchy Company  
Palm Beach, FL

### Secretary

**Robert L. Traynham II, PhD**  
Executive Vice President, Public Affairs  
& Strategic Initiatives  
AHIP  
Washington, DC

### Treasurer

**Donald Dye**  
Chairman, Sky Lake Partners  
New York, NY

## TRUSTEES

**Amy Andelson**  
Screenwriter/Author  
Los Angeles, CA

**Glenn Isaacson**  
President, New York Region  
Bradford Allen  
New York, NY

**Michael Lorber**  
Senior Vice President  
Douglas Elliman Real Estate  
New York, NY

**Tony Mancilla**  
Co-Founder and President, Savanty  
Tampa, FL

**Aron Marquez**  
Founder and Executive Chairman  
Wildcat Oil Tools, LLC  
Midland, TX

**Laurence Milstein**  
Co-Founder, PRZM  
New York, NY

**Cindy Rachofsky**  
Philanthropist  
Dallas, TX

**Vin Roberti**  
Chairman  
Roberti Global  
Washington, DC

**Jeffrey Schoenfeld**  
Partner  
Head of Global Institutional Business  
Development & Relationship Management  
Brown Brothers Harriman  
New York, NY

**Mervyn F. Silverman, MD, MPH**  
President  
Mervyn F. Silverman Associates  
Crockett, CA

**Phill Wilson**  
Founder and CEO (retired)  
Black AIDS Institute  
Los Angeles, CA



*Dr. Lishomwa Ndhlovu, Chair, amfAR's Scientific Advisory Committee, presenting at IAS 2023*  
(Photo © Max Mason-Hubers / IAS)

## IN MEMORIAM

**Mathilde Krim, PhD**  
Founding Chairman

**Dame Elizabeth Taylor**  
Founding International Chairman

**Arthur J. Ammann, MD**  
**Arlen Andelson**  
**Sheldon W. Andelson, Esq**  
**Zev Braun**  
**Arnold W. Klein, MD**  
**Mrs. Albert D. Lasker**  
**Jonathan M. Mann, MD, MPH**  
**Maxine Mesinger**  
**Pauline Phillips**  
**Natasha Richardson**  
**Allan Rosenfield, MD**  
**Peter Scott, Esq.**  
**Wallace Sheft, CPA**  
**Tom Stoddard**  
**Joel D. Weisman, DO**

## SCIENTIFIC ADVISORY COMMITTEE

\*Adjunct Member

Chair  
**Lishomwa Ndhlovu, MD, PhD**  
Professor  
Division of Infectious Diseases  
Weill Cornell Medicine

**Celina Abreu, PhD\***  
Research Associate  
Department of Molecular &  
Comparative Pathobiology  
School of Medicine  
Johns Hopkins University

**José Alcami, MD, PhD\***  
Head of AIDS Immunopathogenesis Unit  
National Centre of Microbiology  
Instituto de Salud Carlos III

**Petronela Ancuta, PhD\***

Professor  
Department of Microbiology,  
Infectiology and Immunology  
Université de Montréal

**Deborah J. Anderson, PhD**

Professor of Obstetrics/Gynecology and  
Virology, Immunology & Microbiology  
Chobanian & Avedisian School of Medicine  
Boston University

**Warren Andiman, MD**

Professor Emeritus of Pediatrics  
Department of Pediatric Infectious Diseases  
Yale School of Medicine

**Patrick Arbuthnot, MD\***

Professor and Director  
Wits/SAMRC Antiviral Gene Therapy  
Research Unit  
South African Medical Research Council (SAMRC)

**Nancie M. Archin, PhD\***

Assistant Professor of Medicine  
Division of Infectious Diseases  
Department of Medicine  
The University of North Carolina at Chapel Hill

**Samuel Bosomprah, MSc, PhD\***

Senior Lecturer  
Department of Biostatistics  
University of Ghana

**Jason Brenchley, PhD\***

Senior Investigator  
Laboratory of Viral Diseases,  
Barrier Immunity Section  
National Institute of Allergy  
and Infectious Diseases  
National Institutes of Health

**Shilpa Buch, PhD\***

Professor  
Department of Pharmacology and  
Experimental Neuroscience  
University of Nebraska, Medical Center

**Dennis R. Burton, PhD**  
Director, Scripps CHAVD  
Chair, Department of Immunology  
and Microbiology  
The Scripps Research Institute

**Salvatore T. Butera, DVM, PhD**  
Chief Operating Officer  
Consortium for HIV/AIDS Vaccine  
Development (CHAVD)  
The Scripps Research Institute

**Edward Campbell, PhD**  
Professor  
Department of Microbiology and Immunology  
Loyola University at Chicago

**David B. Clifford, MD**  
Melba and Forest Seay Professor of Clinical  
Neuropharmacology in Neurology  
Washington University School of Medicine

**Grant Colfax, MD**  
Director  
San Francisco Department of Public Health

**Deborah Jean Cotton, MD, MPH**  
Emeritus Professor, Medicine  
Chobanian & Avedisian School of Medicine  
Boston University

**Bryan R. Cullen, PhD, DSc**  
James B. Duke Professor of Molecular  
Genetics and Microbiology  
Founding Director, Duke University  
Center for Virology  
Duke University Medical Center

**Susanna Cunningham-Rundles, PhD**  
Professor Emerita of Research Immunology  
in Pediatrics  
Department of Pediatrics  
Weill Cornell Medical College

**Richard Thomas D'Aquila, MD**  
The Howard Taylor Ricketts, MD, Professorship  
Division of Infectious Diseases  
Associate Vice President of Research  
Feinberg School of Medicine  
Northwestern University

**Zeger Debyser, MD, PhD\***  
Professor  
Molecular Virology and Gene Therapy Unit  
Department of Pharmaceutical and  
Pharmacological Sciences  
Katholieke Universiteit Leuven

**Sherry Deren, PhD**  
Founding Director Emeritus  
Center for Drug Use and HIV Research  
Visiting Research Professor  
New York University School of Public Health

**Roger Detels, MD, MS**  
Distinguished Research Professor of  
Epidemiology and Infectious Diseases  
Fielding School of Public Health  
University of California, Los Angeles

**Carl W. Dieffenbach, PhD**  
Director, Division of AIDS (DAIDS)  
National Institute of Allergy and Infectious  
Diseases  
National Institutes of Health

**Daniel C. Douek, MD, PhD**  
Chief, Genome Analysis Core  
Chief, Human Immunology Section  
Vaccine Research Center  
National Institute of Allergy and Infectious  
Diseases  
National Institutes of Health

**D. Peter Drotman, MD, MPH**  
Editor-in-Chief  
Emerging Infectious Diseases  
Centers for Disease Control and Prevention

**Anke A. Ehrhardt, PhD**  
Director, Division of Gender, Sexuality, & Health  
Program for the Study of LGBT Health  
Professor, Medical Psychology  
New York State Psychiatric Institute/Columbia  
University

**Homayoon Farzadegan, PhD**  
Professor  
Department of Epidemiology  
Johns Hopkins Bloomberg School of Public  
Health

**Sarah Fidler, BSc, MBBS, FRCP, PhD\***  
Professor of HIV and Communicable Diseases  
Faculty of Medicine, Department of  
Infectious Disease  
Imperial College London

**Dianne M. Finkelstein, PhD**  
Professor of Medicine, Emerita  
Massachusetts General Hospital

**Gerald Friedland, MD**  
Professor Emeritus of Medicine and  
Epidemiology and Public Health  
Senior Research Scientist, Infectious Diseases  
Yale School of Medicine

**Christina Gavegnano, PhD\***  
Assistant Professor  
Department of Pathology and Laboratory  
Medicine  
School of Medicine  
Emory University

**Howard E. Gendelman, MD**  
Margaret R. Larson Professor of Internal  
Medicine and Infectious Diseases  
Chair, Department of Pharmacology and  
Experimental Neuroscience  
University of Nebraska Medical Center

**Nancy L. Haigwood, PhD**  
Professor and Director  
Oregon National Primate Research Center  
Oregon Health & Science University

**Alon Herschhorn, PhD\***  
Associate Professor of Medicine  
Division of Infectious Diseases and  
International Medicine  
University of Minnesota

**Charles H. Hinkin, PhD**  
Professor Emeritus  
Department of Psychiatry and Biobehavioral  
Sciences  
David Geffen School of Medicine  
University of California, Los Angeles

**David D. Ho, MD**  
Professor of Microbiology and Immunology  
Clyde '56 and Helen Wu Professor of Medicine  
Director, Aaron Diamond AIDS Research Center  
Columbia University

**Ya-Chi Ho, MD, PhD\***  
Assistant Professor Term  
Director of Graduate Studies  
Microbiology PhD Program of Biological  
and Medical Sciences  
Yale School of Medicine

**Thomas J. Hope, PhD**  
Professor, Department of Cell and Molecular  
Biology, McCormick School of Engineering  
and Obstetrics and Gynecology  
Feinberg School of Medicine  
Northwestern University

**Shiu-Lok Hu, PhD**  
Professor Emeritus  
Department of Pharmaceutics  
School of Pharmacy  
University of Washington

**Nuria Izquierdo-Useros, PhD\***  
Principal Investigator  
Pathogens, Immunity, Signalization and Applied  
Therapies  
IrsiCaixa, Institut de Recerca de la Sida

**Richard Jefferys**  
Basic Science, Vaccines, and Cure Project  
Director  
Treatment Action Group

**R. Brad Jones, PhD\***  
Associate Professor  
Division of Infectious Diseases  
Department of Microbiology and Immunology  
Weill Cornell Medicine

**Jonathan Karn, PhD\***  
Professor and Chair  
Department of Molecular Biology  
and Microbiology  
Professor, Department of Biochemistry  
School of Medicine  
Case Western Reserve University

**Mary F. Kearney, PhD\***  
Deputy Director, HIV Dynamics  
and Replication Program  
Head, Translational Research Section  
Center for Cancer Research  
National Cancer Institute  
National Institutes of Health

**Vineet N. KewalRamani, PhD**  
Head, Model Development Section  
Center for Cancer Research  
National Cancer Institute  
National Institutes of Health

**Scott Kitchen, PhD**  
Professor-in-Residence  
David Geffen School of Medicine  
University of California, Los Angeles

**Richard S. Kornbluth, MD, PhD**  
President and Chief Scientific Officer  
Multimeric Biotherapeutics, Inc.



**Richard Koup, MD**

Deputy Director, Vaccine Research Center  
Chief, Immunology Laboratory and Immunology  
Section  
National Institute of Allergy and Infectious  
Diseases  
National Institutes of Health

**Deanna Kulpa, PhD\***

Associate Professor  
Department of Pathology & Laboratory Medicine  
Emory University School of Medicine

**Priti Kumar, PhD\***

Associate Professor  
Infectious Diseases and Microbial Pathogenesis  
Yale School of Medicine

**Nathaniel R. Landau, PhD**

Professor  
Department of Microbiology  
New York University Grossman  
School of Medicine

**Alan L. Landay, PhD**

Professor  
Departments of Internal Medicine  
and Microbial Pathogens and Immunity  
Vice Chair for Research, Department  
of Internal Medicine  
Chief, Division of Translational  
and Precision Medicine  
Rush University Medical Center

**Michael Lederman, MD**

Professor of Medicine, Emeritus  
Professor of Pathology, Microbiology/  
Molecular Biology and Biomedical Ethics  
Case Western Reserve University School  
of Medicine

**Tun-Hou Lee, DSc**

Professor of Virology, Emeritus  
Immunology and Infectious Diseases  
Harvard T.H. Chan School of Public Health

**Michael J. Leibowitz, MD, PhD**

Professor  
Department of Medical Microbiology  
and Immunology  
University of California, Davis

**Judy Lieberman, MD, PhD**

Endowed Chair, Cellular and Molecular  
Medicine  
Boston Children's Hospital  
Professor of Pediatrics  
Harvard Medical School

**Herbert Kim Lyerly, MD**

George Barth Geller Distinguished Professor of  
Immunology  
Professor in Surgery, Immunology, Pathology  
Director of the Center of Applied Therapeutics  
Member, Duke Cancer Institute  
Duke University School of Medicine

**David M. Margolis, MD**

Sarah Graham Kenan Distinguished  
Professor of Medicine  
Professor Microbiology and Immunology,  
and Epidemiology  
Director, UNC Cure Center  
Department of Medicine  
University of North Carolina at Chapel Hill

**Matthew Marsden, PhD\***

Assistant Professor, Microbiology and Molecular  
Genetics, and Infectious Diseases  
School of Medicine  
University of California, Irvine

**Kenneth Hugh Mayer, MD**

Infectious Disease Attending &  
Director of HIV Prevention Research  
Beth Israel Deaconess Medical Center

**Joseph "Mike" McCune, MD, PhD**

Professor of Medicine  
University of California, San Francisco  
Head, Frontiers  
Bill and Melinda Gates Foundation

**Donna Mildvan, MD**

Professor of Medicine  
Ichan School of Medicine  
Mount Sinai

**Walther Mothes, PhD\***

Paul B. Beeson Professor of Medicine  
Professor of Microbial Pathogenesis  
Yale University

**Patrick Musonda, PhD\***

Associate Professor, Medical Statistics  
School of Public Health  
University of Zambia

**Jay A. Nelson, PhD**

Professor, VGTI-Vaccine and  
Gene Therapy Institute  
School of Medicine  
Oregon Health & Science University

**David O'Connor, PhD\***

Professor of Pathology & Laboratory Medicine  
The UW Medical Foundation  
University of Wisconsin-Madison

**Nancy Padian, PhD, MPH**

Adjunct Professor of Epidemiology  
School of Public Health  
University of California, Berkeley

**Savita Pahwa, MD**

Professor of Microbiology and Immunology  
Professor in Pediatrics and Medicine  
Director of the Miami Center for AIDS Research  
University of Miami Leonard M. Miller School of  
Medicine

**Tristram G. Parslow, MD, PhD**

Professor Emeritus  
Department of Pathology and  
Laboratory Medicine  
Emory University School of Medicine

**Matija Peterlin, MD**

Professor Emeritus  
Department of Medicine  
University of California, San Francisco

**Lynn Pulliam, PhD**

Professor  
Department of Laboratory Medicine  
and Medicine  
University of California, San Francisco  
Veterans Affairs Medical Center

**Lee Ratner, MD, PhD**

Alan A. and Edith L. Wolff Professor of Oncology  
John T. Milliken Department of Medicine  
Washington University School of Medicine

**Andrew Patrick Rice, PhD**

Nancy Chang, PhD Endowed Professorship  
Department of Molecular Virology and  
Microbiology  
Baylor College of Medicine

**Simone Richardson, PhD\***

Postdoctoral Fellow  
Antibody Immunity Research Unit  
National Institute for Communicable  
Diseases (NICD)  
University of the Witwatersrand, South Africa

**Leah Rubin, PhD, MA, MPH\***

Professor, Neurology, Molecular & Comparative  
Pathobiology, Psychiatry & Behavioral Sciences  
Co-Founder/Co-Director, Brain Health Program  
Johns Hopkins University

**Ruth M. Ruprecht, MD, PhD**

Department of Microbiology, Immunology &  
Molecular Genetics  
University of Texas San Antonio  
Texas Biomedical Research Institute  
Department of Biology  
University of Louisiana at Lafayette

**Rachel Rutishauser, MD, PhD\***

Associate Professor, Medicine  
School of Medicine  
University of California, San Francisco

**Ivan Sadowski, PhD\***

Professor, Biochemistry and Molecular Biology  
Faculty of Medicine  
University of British Columbia

**Asier Sáez-Cirión, PhD\***

Associate Professor  
Head of the Viral Reservoirs and  
Immune Control Unit  
Institut Pasteur

**Frederick A. Schmitt, PhD**

Professor  
Department of Neurology  
Sanders Brown Center on Aging  
University of Kentucky

**Gerald Schochetman, PhD**

Senior Director  
Diagnostics Research for Strategic  
and Emerging Markets Initiatives  
Abbott Laboratories

**Robert T. Schooley, MD**

Infectious Disease Specialist  
Chief, Division of Infectious Diseases  
University of California, San Diego Health

**Janet Siliciano, PhD\***

Professor  
Department of Medicine  
Johns Hopkins University

**Pamela J. Skinner, PhD\***

Professor  
Department of Veterinary and  
Biomedical Sciences  
University of Minnesota

**Gail Skowron, MD**  
Adjunct Professor of Medicine  
Brown University

**Nikunj Somia, PhD\***  
Associate Professor  
Genetics, Cell Biology and Development  
University of Minnesota

**Leonidas Stamatatos, PhD**  
Member  
Fred Hutchinson Cancer Center  
Vaccine and Infectious Disease Division  
Immunology and Vaccine Development Program

**Mario Stevenson, PhD**  
Professor of Medicine  
Chief, Division of Infectious Diseases  
University of Miami Leonard M. Miller  
School of Medicine

**Rebecca Veenhuis, PhD\***  
Assistant Professor of Molecular &  
Comparative Pathobiology  
School of Medicine  
Johns Hopkins University

**David Vlahov, RN, PhD**  
Professor Emeritus  
School of Nursing  
University of California, San Francisco

**David J. Volsky, PhD**  
Professor of Medicine and Pathology  
Icahn School of Medicine at Mount Sinai  
Director of Molecular Virology Laboratory  
Department of Medicine  
Mount Sinai St. Luke's and Roosevelt Hospitals

**James Voss, PhD\***  
Institute Investigator  
Department of Immunology and Microbiology  
Scripps Research

**Steven S. Witkin, PhD**  
Professor Emeritus of Immunology  
in Obstetrics and Gynecology  
Weill Cornell Medical College

**Peter R. Wolfe, MD**  
Associate Clinical Professor  
David Geffen School of Medicine  
University of California, Los Angeles

**Richard T. Wyatt, PhD**  
Professor  
Department of Immunology and Microbiology  
Senior Director, Viral Immunology, IAVI Center  
for Neutralizing Antibodies  
Scripps Research

**Jerome Zack, PhD\***  
Distinguished Professor and Department Chair  
Department of Microbiology, Immunology &  
Molecular Genetics  
Co-Director, UCLA AIDS Institute  
University of California, Los Angeles

**Anjie Zhen, PhD\***  
Assistant Adjunct Professor  
School of Medicine  
University of California, Los Angeles

## PROGRAM ADVISORY COUNCIL

**Mervyn F. Silverman, MD, MPH (Chairman)**  
President  
Mervyn F. Silverman Associates, Inc.

**Judith D. Auerbach, PhD**  
Science & Policy Consultant  
Professor, School of Medicine  
University of California, San Francisco

**David Bloom, PhD**  
Chair, Dept. of Population and  
International Health  
Harvard School of Public Health

**Tim Brown, PhD**  
Senior Fellow  
The East-West Center

**Daniel Douek, MD, PhD**  
Chief, Human Immunology Section  
Vaccine Research Center  
National Institutes of Health

**Elvin H. Geng, MD, MPH**  
Professor of Medicine  
Director, Center for Dissemination and  
Implementation at the Institute for Public Health  
Director, Dissemination and Implementation  
Research Core, Institute for Clinical and  
Translational Science  
Division of Infectious Diseases  
John T. Milliken Department of Internal Medicine  
Washington University in St. Louis

**Katherine Luzuriaga, MD**  
Professor, Molecular Medicine, Pediatrics  
and Medicine  
University of Massachusetts Medical School

**Kenneth H. Mayer, MD**  
Infectious Disease Attending & Director of HIV  
Prevention Research, Beth Israel Deaconess  
Medical Center, Boston

Visiting Professor of Medicine  
Harvard Medical School

Medical Research Director  
The Fenway Institute/Fenway Health

**Jeffrey L. Sturchio, PhD**  
Senior Associate, Global Health Policy Center  
Center for Strategic and International Studies

Chairman of the Board, Friends of the Global  
Fight Against AIDS, TB, and Malaria

Chairman of the Board  
Corporate Council on Africa

Visiting Scholar, Institute for Applied Economics,  
Global Health & the Study of Business  
Enterprise, Johns Hopkins University

Member, The Council on Foreign Relations

**Phill Wilson**  
Founder and CEO (retired)  
Black AIDS Institute

## MANAGEMENT GROUP

**Kevin Robert Frost**  
Chief Executive Officer

**Anthony Ancona**  
Vice President and Director, Human Resources

**Susan J. Blumenthal, MD, MPA**  
Senior Policy and Medical Advisor

**Kyle Clifford**  
Incoming Chief Executive Officer

**Shawn Davidson**  
Chief Financial and Operating Officer

**Sebastian Gheith**  
General Counsel

**Andrea Gramatica, MSc, PhD**  
Vice President and Director of Research

**Jeffrey Laurence, MD**  
Senior Scientific Consultant for Programs

**Karen Mateo**  
Vice President and Director, Public Information

**Gregorio Millett, MPH**  
Vice President and Director, Public Policy

**Annette Sohn, MD, PhD**  
Vice President and Director, TREAT Asia

**Cicely S. Wootan**  
Chief Development Officer

*As of September 2025*



## CONNECT WITH US



@amfar



@amfARthefoundationforaidsresearch



@amfARofficial



@amfAR



@amfAR



[linkedin.com/company/amfAR](https://www.linkedin.com/company/amfAR)

# amfAR

**The Foundation for AIDS Research**

NEW YORK  
120 Wall Street, 13th Floor  
New York, NY 10005-3908  
(212) 806-1600

WASHINGTON, D.C.  
1100 Vermont Avenue, NW  
Suite 600  
Washington, DC 20005  
(202) 331-8600

BANGKOK, THAILAND  
TREAT Asia  
Exchange Tower  
388 Sukhumvit Road, Suite 2104  
Klongtoey, Bangkok 10110  
Thailand  
+66 (0)2 663 7561

[www.amfar.org](http://www.amfar.org)



amfAR meets the BBB  
Wise Giving Alliance's  
Standards for Charity  
Accountability.

